CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 58 enrolled
Drug / intervention
Pegylated Liposomal Doxorubicin hydrochloridedrug
Likely dose
Pegylated Liposomal Doxorubicin hydrochloride 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00727961
NCT00727961Phase 4Completed
CompareCT.gov

Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy.

Merck Sharp & Dohme LLC·interventional·Posted Aug 5, 2008·Updated Jun 8, 2017

In Brief

A Phase 4 clinical trial evaluating Pegylated Liposomal Doxorubicin hydrochloride for Ovarian Neoplasms. Completed, enrolled 58 participants.

Detailed Summary

The aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with CAELYX (50 mg/m\^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian cancer, resistant to previous platinum therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2008
Enrollment StartNov 9, 2004
Primary CompletionJan 10, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.9 years ago

Interventions

Pegylated Liposomal Doxorubicin hydrochloridedrug

Caelyx Intravenous, 50 mg/m\^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles